Michael Pisetsky Sells 1,799 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 1,799 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $12.95, for a total value of $23,297.05. Following the transaction, the senior vice president directly owned 284,175 shares in the company, valued at $3,680,066.25. The trade was a 0.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

SiBone Stock Performance

NASDAQ SIBN opened at $13.12 on Friday. SiBone has a one year low of $12.15 and a one year high of $21.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.21 and a current ratio of 8.55. The company has a market capitalization of $579.44 million, a price-to-earnings ratio of -29.82 and a beta of 0.77. The company’s 50-day simple moving average is $14.62 and its two-hundred day simple moving average is $16.38.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. The company had revenue of $56.35 million during the quarter, compared to the consensus estimate of $56.26 million. Equities analysts forecast that SiBone will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On SiBone

Several large investors have recently made changes to their positions in SIBN. ANTIPODES PARTNERS Ltd acquired a new stake in SiBone in the fourth quarter valued at approximately $29,000. Royal Bank of Canada raised its position in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares during the period. Caitong International Asset Management Co. Ltd raised its position in SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after acquiring an additional 1,941 shares during the period. State of Alaska Department of Revenue purchased a new position in SiBone during the third quarter valued at $39,000. Finally, Kemnay Advisory Services Inc. purchased a new position in SiBone during the fourth quarter valued at $53,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SIBN. Wall Street Zen upgraded SiBone from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. TD Cowen upped their price objective on shares of SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Canaccord Genuity Group raised their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Truist Financial reiterated a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of SiBone in a research note on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.